Heterozygous familial hypercholesterolemia (FH) is a relatively common autosomal dominant disorder, which is characterized by elevated plasma concentrations of low density lipoprotein (LDL) cholesterol and early coronary heart disease. FH results from mutations in the gene encoding the LDL receptor
Functional analysis of LDLR promoter and 5′ UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia
✍ Scribed by Isabel De Castro-Orós; Sandra Pampín; Alfonso Bolado-Carrancio; Aguirre De Cubas; Lourdes Palacios; Nuria Plana; Jose Puzo; Esperanza Martorell; Marianne Stef; Luis Masana; Fernando Civeira; Jose Carlos Rodríguez-Rey; Miguel Pocoví
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 252 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1059-7794
No coin nor oath required. For personal study only.
✦ Synopsis
Familial hypercholesterolemia (FH) is a dominant disorder due to mutations in the LDLR gene. Several mutations in the LDLR promoter are associated with FH. Screening of 3,705 Spanish FH patients identified 10 variants in the promoter and 5 0 UTR. Here, we analyse the functionality of six newly identified LDLR variants. Mutations located in the LDLR promoter regulatory elements R2 and R3 (c.À155_-150delACCCCinsTTCTG-CAAACTCCTCCC, c.À136C4G, c.À140C4G, and c.À140C4T) resulted in 6 to 15% residual activity in reporter expression experiments and changes in nuclear protein binding affinity compared to wild type. No reduction was observed when cells were transfected with c.À208T, c.À88A, and c.À36G mutant fragments. Our results indicate that mutations localized in R2 and R3 are associated with hypercholesterolemia, whereas mutations outside the LDLR response elements are not a cause of FH. This data emphasizes the importance of functional analysis of variants in the LDLR promoter to determine their association with the FH phenotype.
📜 SIMILAR VOLUMES
We used the single strand conformation polymorphism (SSCP) method to investigate 36 apparently unrelated Spanish patients with familial hypercholesterolemia (FH) for mutations in the promoter region and the 18 exons and their flanking intron sequences of the low density lipoprotein receptor (LDLR) g